Abstract
The two methods of high performance liquid chromatography (HPLC) and bioassay have been reproted for determining arbekacin sulfate (ABK) in serum. The former method is inappropriate for clinical use due to inconvenient sample preparation, and the latter is insufficient because of its long assay time or influence of concomitant antibiotics. Therefore, the “TDx dibekacin kit” (TDx-DBK) for determination of serum arbekacin was used and evaluated in an effort to develop a practical method.
The calibration curve obtained demonstrated a good correlation (r=0.9993): the regression equation was Y=0.75X+ 1.15 within the 0-10μg/ml range. The coefficient of variation of within-run precision for five concentrations of arbekacin in serum (0.5, 1.0, 2.5, 5.0, 10. 0μg/ml) was less than 5% and that of between-run precision for three concentrations (1.0, 5.0, 10.0 μg/ml) was lesst han 7%.
The serum ABK (24 samples) concentrations were determined using this method and compared with those determined by HPLC. Good agreement was noted between the results derived by this TDx-DBK method and those by HPLC, where the correlation coefficient was more than 0.957. These results indicate that this TDx-DBK method may be useful for serum drug-level monitoring of patients undergoing ABK therapy.
